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Background: Participation bias is a well-known phenomenon in epidemiologic research, where individuals
consenting to research studies differ from individuals who are not able or willing to participate. These dissimilarities
may limit the generalizability of results of research studies. Quantification of the participation bias is essential for the
interpretation of research findings.
Methods: The Ontario HIV Treatment Network Cohort Study (OCS) is an ongoing open cohort study of HIV positive
individuals receiving care at one of 11 sites in Ontario. OCS participants from 4 sites were compared to non-
participants (those who declined or were not approached) at those sites with regard to gender, age, HIV risk factor,
CD4 count and viral load (VL). Generalized logit regression models were used to identify predictors of declining to
participate or not being approached to participate.
Results: Compared to participants (P) in the OCS, individuals who declined to participate (D) and those who were
not approached (NA) were slightly younger (D:45, NA:44 vs P:46), less likely to be male (D: 71%, NA:75% vs P:88%),
less likely to be Caucasian (D:41%, NA:57% vs P:72%) and less likely to be Canadian-born (D: 39%, NA: 52% vs P:
69%). Patients who were not approached to participate were less likely to have VL < 50 copies/mL than other
patients (D: 75%, NA: 62%, P: 74%) and had lower CD4 counts than OCS participants (D: 450 cells/mm3, NA: 420
cells/mm3, P: 480 cells/mm3).
Conclusions: Significant demographic and clinical differences were found between OCS participants and
non-participants. Extrapolation of research findings to other populations should be undertaken cautiously.
Keywords: Participation bias, Selection bias, HIV, Generalizability, RepresentativenessBackground
Participation bias, also known as volunteer bias and re-
cruitment bias, is a well-known phenomenon in epide-
miologic studies where research volunteers differ in
important ways from individuals who decline to partici-
pate [1-3]. Further, individuals who are not approached
to participate in research studies may be even more dis-
similar from participants than those who are approached
but who decline. Before generalizing the results of a* Correspondence: jraboud@uhnresearch.ca
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reproduction in any medium, provided the orresearch project to a wider population of interest, it is
important to quantify the differences between partici-
pants of a research study and individuals from the same
population who did not participate.
Population-based studies using non-nominal data from
administrative databases or medical charts have been in-
valuable in HIV research for determining incidence,
prevalence and natural history of specific HIV-related
conditions [4-8]. While these studies undergo ethics re-
view, individual patient consent is not usually required,
so that participation bias does not influence the compos-
ition of the study sample.
In contrast, studies of health-related quality of life,
mental health, social support and other psychosociall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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participation due to the very nature of the research
[9-12]. Although these studies provide important in-
sights into the dynamics and interplay of clinical HIV
disease with social factors, the time commitment to
complete the questionnaires and willingness to share
personal details may yield a study sample which is not
representative of the population from which it is drawn.
The Ontario HIV Treatment Network (OHTN) Cohort
Study (OCS) [13] is a voluntary clinic-based cohort study
of HIV positive individuals living in Ontario, Canada
which administers annual interviews to participants. To
assess the generalizability of this cohort to HIV positive
individuals in care at the recruiting sites, we compared
demographic and clinical characteristics of individuals
who consented to participate to those of persons from
those sites who declined to participate or who were not
approached to participate.
Methods
Ontario HIV Treatment Network Cohort Study (OCS)
The OCS was designed to collect clinical and socio-
behavioural information from people with HIV in
Ontario in order to better understand HIV infection,
treatment strategies, and their complications; and to
improve access to care and treatment for people living
with HIV [13]. The OCS was initiated in 2007 and in-
cludes both new enrollees as well as persons who had pre-
viously participated in the HIV Ontario Observational
Database (HOOD) [14] and consented to continue their
enrolment.
HIV positive adults were recruited from 11 sites in
Ontario, including hospital-based HIV clinics, hospital-
based family practice units, and primary care physicians
in private practice who specialize in HIV. To be eligible,
participants had to have laboratory evidence of HIV in-
fection and be a patient at a currently recruiting site.
Approximately 75% of viral load tests conducted at the
Ontario Public Health Laboratories, which processes all
viral load measurements for clinical care in the province,
are submitted by these 11 OCS sites [13]. All study par-
ticipants sign informed consent prior to participation in
the OCS. The OCS has been approved by the University
of Toronto Ethics Review Board as well as the ethics re-
view boards of individual sites.
Data collection
Since September 2007, OCS participants have completed
an annual interviewer-administered questionnaire. Two
versions of the questionnaire were used: a 20 minute
“core” version and a 90–120 minute “extended” version.
The core questionnaire collects information on demo-
graphic, smoking and alcohol use, health related qual-
ity of life, mental health. The 90-minute extendedquestionnaires collects additional information on psycho-
social measures such as social support, coping, stigma, re-
cent life events and ongoing problems. The allocation of
questionnaire version to sites was determined based on
the preferences of site Principal Investigators and the
availability of resources at each site. The core version was
administered at seven sites (Maple Leaf Medical Clinic
(MLMC) in Toronto, Ottawa Hospital Immunodeficiency
Clinic in Ottawa, Windsor Regional Hospital HIV Care
Program, HAVEN clinic at the Sudbury Regional Hospital
in Sudbury, HIV Clinic in Hotel Dieu Hospital in
Kingston, Hamilton Health Sciences’ Chedoke Hospital in
Hamilton and St. Joseph’s Hospital in London). The
extended version was administered at four sites, all in
Toronto (University Health Network (UHN), Sunnybrook
Health Sciences Centre and two sites at St Michael’s
Hospital). Participants who enrolled at sites adminis-
tering the core questionnaire were compensated $20
CDN, whereas those who enrolled at sites adminis-
tering the extended questionnaire were compensated
$50 CDN.
At most sites, clinical data were abstracted from med-
ical charts every six months including CD4 counts, and
viral load measurements, dates of antiretroviral medica-
tions, diagnostic codes, adverse events and hospitaliza-
tions. At sites which had established databases for
patient care and approval from a local research ethics
board, clinical chart data for consenting participants
were electronically transferred to the OCS.
Representativeness study
This representative study was designed to assess the
generalizability of participants enrolled in the OCS by
comparing them to persons from the clinic sites who de-
clined to participate or who were not approached to par-
ticipate. All 11 OCS sites were invited to participate in
this study and investigators at the following four sites
agreed to participate: UHN, MLMC, Ottawa Hospital
and Windsor Regional Hospital HIV Care Program.
UHN and MLMC are located in Toronto, Canada’s lar-
gest city with a population of 2,500,000. UHN is a teach-
ing hospital affiliated with the University of Toronto
located in a downtown setting. The Immunodeficiency
Clinic at UHN has an active patient population of 1000
comprised largely of men having sex with men (MSM)
(48%) and recent immigrants (46% foreign born).
MLMC is a community-based clinic providing both pri-
mary care and HIV specialty care, with a patient popula-
tion of approximately 2600, comprised largely of MSM.
The Windsor Regional Hospital is located in Essex
County, Ontario (population 400,000). The HIV Care
Program serves approximately 260 patients with the full
spectrum of HIV risk factors. The Ottawa HIV Clinic is
located in Ottawa (population 800,000), is affiliated with
Raboud et al. BMC Medical Research Methodology 2013, 13:31 Page 3 of 8
http://www.biomedcentral.com/1471-2288/13/31the University of Ottawa and has an active population of
800, with a significant number of patients infected
through injection drug use.
Two types of non-participants were included in the ana-
lysis: 1) individuals who declined to participate or with-
drew from the study within two weeks whereupon no data
was transmitted to the OCS, and 2) individuals who were
not approached to participate in the study. The time pe-
riods during which participants who consented to partici-
pate in the OCS were compared to non-participants were:
UHN (February, 2008 – September, 2009) , MLMC
(March, 2008 – September, 2009), Ottawa Hospital
(February, 2008 – September, 2009) and Windsor Regional
Hospital (February 2008 – August, 2009). Patients in
HOOD who died or were lost to follow-up and whose
data was rolled over into the OCS were not included
in this analysis.
Data for the non-participants were obtained from
clinic databases for MLMC, UHN and Ottawa and by
manual chart review at Windsor Regional Hospital. Each
of the three clinic databases contained variables noting
the date that each patient was approached to participate
in the OCS and whether or not they agreed to partici-
pate. Patients who consented were classified as “partici-
pants”, patients who were approached but did not agree
to participate were classified as “declined” and patients
who were not approached during the study period were
classified as “not approached”. Patients who were not
seen in the clinic during the study period were excluded
from the analysis. Additionally, patients at MLMC seen
during the study period after the site recruitment quota
had been reached were also excluded from the analysis.
At Windsor Regional Hospital, a single study nurse was
responsible for approaching all patients to participate
in the OCS and provided lists of patients who de-
clined to participate and patients who had not been
approached. Data for OCS participants were obtained
from the OCS database.
This study was approved by the Ethics Review Boards
of each of the four participating sites.
Statistical methods
Demographic and clinical characteristics were compared
between participants and non-participants of the OCS.
Baseline demographic, clinical and social characteristics
were summarized within groups using medians and inter-
quartile ranges (IQR) for continuous variables and fre-
quencies and percentages for categorical variables. For
patients who consented, refused to participate or were not
approached to participate, baseline values were those at
the time of consent, refusal or closest to December 2008
(the midpoint of the study period), respectively.
Characteristics were compared between individuals
from the four sites participating in the representativenessstudy and the other seven OCS sites using chi square tests
or Fisher’s exact test as appropriate for categorical vari-
ables and Wilcoxon rank sum tests for continuous vari-
ables. Characteristics were then compared between
participants who consented, individuals who refused and
those who were not approached at the four sites partici-
pating in the representativeness study using chi square
tests or Fisher’s exact test as appropriate for categorical
variables and Kruskal-Wallis tests for continuous vari-
ables. Multivariable generalized logit regression models
were used to identify demographic and clinical character-
istics of participants which were associated with the out-
comes of declining to participate in the study and not
being approached to participate in the study, relative to in-
dividuals who consented to participate in the study.
Results
As of September 2009, 3106 consented participants were
enrolled in the OCS, of whom 2925 had completed at
least one annual questionnaire. Of these, 1155 partici-
pants had completed the extended questionnaire and
1770 participants had completed the core questionnaire.
Overall, 85% were male, the median age was 46 (IQR
40–52), 72% were Caucasian, 71% were MSM, 12% were
infected with HIV through injection drug use, the me-
dian CD4 count was 471 (IQR 330–650) and 73% had
viral load < 50 copies/ml at the time of OCS consent,
which was a median of 0 days (IQR 0, 59) before the
date of completing the first questionnaire (Table 1).
Characteristics of patients at the four sites which par-
ticipated in the representativeness study were compared
to those of patients in the seven sites that did not par-
ticipate (Table 1). Individuals at sites participating in the
representativeness study were of similar age, had higher
proportions of males and men having sex with men
and had higher levels of education and income than
individuals at sites that did not agree to participate in
the study.
Comparison of participants vs Non-participants
Baseline characteristics were compared between partici-
pants, those invited to participate but who declined and
patients who were not approached (Table 2). Participants
were similar to non-participants with respect to the pro-
portion who had a history of injection drug use. Partici-
pants were slightly older than non-participants, had
been infected with HIV longer, had higher CD4 cell
counts and were more like to be male, MSM, Caucasian,
Canadian-born and be on cART therapy. Individuals
who declined to participate had similar rates of viro-
logic suppression at the time they were approached
to participate as OCS participants but individuals who
were not approached were less likely to have suppressed
viral load.
Table 1 Comparison of OCS participants’ characteristics between the participating and non-participating sites in the
representativeness study
All sites 4 sites in representativeness study Other sites
Characteristics (n=3106) (n=1861) (n=1245) p value
Age 46 (40–52) 46 (40–52) 46 (40–52) 0.77
Male 2628 (85%) 1632 (88%) 996 (80%) <.0001
Risk factor
MSM 2133 (71%) 1429 (77%) 704 (60%) <.0001
IDU 364 (12%) 180 (10%) 184 (16%) <.0001
heterosexual 629 (21%) 325 (18%) 304 (26%) <.0001
Blood product/MTCT 197 (6%) 102 (5%) 95 (8%) 0.009
Race 0.02
Caucasian 2170 (72%) 1329 (72%) 841 (72%)
Black/African 418 (14%) 259 (14%) 159 (14%)
Aboriginal 161 (5%) 83 (4%) 78 (7%)
Other 264 (9%) 176 (10%) 88 (8%)
Born in Canada 2090 (69%) 1264 (69%) 826 (70%) 0.35
Years since HIV+ test 11 (6–17) 12 (5–18) 11 (6–17) 0.41
Cigarette history 0.006
Never 1017 (35%) 623 (35%) 394 (35%)
Former 736 (25%) 479 (27%) 257 (23%)
Current 1161 (40%) 671 (38%) 490 (43%)
Alcohol use 1102 (38%) 718 (40%) 384 (34%) 0.0003
Substance use 614 (21%) 414 (23%) 200 (18%) 0.0002
Education <.0001
High school or lower 929 (32%) 504 (28%) 425 (37%)
Some/completed college 890 (30%) 545 (31%) 345 (30%)
Some/completed university 1102 (38%) 732 (41%) 370 (32%)
Employed 1401 (48%) 920 (52%) 481 (42%) <.0001
Household income <.0001
< 30 K 1062 (40%) 566 (35%) 496 (47%)
30-60 K 612 (23%) 378 (24%) 234 (22%)
60-80 K 298 (11%) 189 (12%) 109 (10%)
> 80 K 693 (26%) 470 (29%) 223 (21%)
General health <.01
Good 2353 (81%) 1466 (82%) 887 (78%)
Fair 464 (16%) 248 (14%) 216 (19%)
Poor 103 (4%) 65 (4%) 38 (3%)
On cART 2497 (80%) 1487 (80%) 1010 (81%) 0.40
CD4 count (cells/mm3) 471 (330–650) 480 (340–650) 460 (310–649) 0.02
VL < 50 copies/mL 2254 (73%) 1379 (74%) 875 (70%) 0.02
OCS Ontario HIV Treatment Network Cohort Study, MSM men who have sex with men, IDU injection drug use, MTCT mother to child transmission, cART
combination antiretroviral therapy, VL viral load.
Numbers are reported as median (interquartile range) or frequency (percentage).
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(Table 3), MSM (OR = 0.31, p<.0001), patients who were
born in Canada (OR = 0.62, p=.01) and patients with alonger time since the first positive HIV test (OR = 0.95
per year, p=.0007) were less likely to decline to partici-
pate in the OCS. Individuals with CD4 counts < 200
Table 2 Comparison of OCS participants to non-participants
from four recruiting sites
Characteristics‡ Consented Declined Not approached
(n =1861) (n =216) (n =502) p value
Site
Windsor 128 (7%) <6 (<3%) 94 (19%) <.0001
UHN 525 (28%) 162 (75%) 226 (45%)
Ottawa 293 (16%) 35 (16%) 123 (25%)
MLMC 915 (49%) <16 (<7%) 59 (12%)
Age 46 (40–52) 45 (37–51) 44 (39–50) 0.008
Male 1632 (88%) 154 (71%) 374 (75%) <.0001
Risk Factor
MSM 1429 (77%) 90 (42%) 229 (47%) <.0001
IDU 180 (10%) 13 (6%) 49 (10%) 0.19
Heterosexual 325 (18%) 93 (43%) 177 (36%) <.0001
Blood product 100 (5%) 10 (5%) 30 (7%) 0.46
Race
Caucasian 1329 (72%) 76 (41%) 240 (57%) <.0001
Black/African 259 (14%) 75 (40%) 129 (31%)
Other 259 (10%) 35 (19%) 49 (11%)
Born in Canada 1264 (69%) 78 (39%) 224 (52%) <.0001
Years since
HIV+ test
12 (5–18) 7 (5–14) 8 (4–13) <.0001










<200 155 (8%) 31 (14%) 70 (15%) <.0001
200-500 851 (46%) 102 (47%) 227 (47%)
>500 853 (46%) 82 (38%) 185 (38%)
VL <50
copies/mL
1379 (74%) 160 (75%) 297 (62%) <.0001
‡ median (interquartile range) or frequency (percent).
OCS Ontario HIV Treatment Network Cohort Study, UHN University Health Network,
MLMC Maple Leaf Medical Clinic, MSM men who have sex with men, IDU injection
drug use, cART combination antiretroviral therapy, VL viral load.
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as individuals with CD4 counts >500 cells/mm3 (OR =
2.20, p=.004). Non mutually exclusive risk factors of
MSM (OR = 0.30, p<.0001), IDU (OR=0.59, p=.04)
and heterosexual contact (OR=0.59, p=.01), a longer
time since the first positive HIV test (OR=0.94 per
year, p<.0001) and suppressed viral load (OR = 0.59,
p=.002) were associated with a lower likelihood of not
being approached to participate in the OCS. After
adjusting for these covariates, age and gender were not
associated with declining to participate in the OCS or
not being approached to participate in the OCS. Race
was not included in this model due to the unavailabil-
ity of data on race at one of the sites for non-
participants of the OCS.Refusal rates among patients approached to participate
in the study varied among sites (2% - 24%), with the
highest rate observed at the site which administered the
extended questionnaire. The most common reasons site
coordinators recalled for declining to participate in the
OCS were potential candidates being “too busy”, “not in-
terested” and having concerns about privacy. The most
common reasons given for not approaching patients to
participate in the OCS included language barriers, per-
ceived fear of disclosure, patient newly diagnosed, men-
tal illness, drug addiction, patient too sick, “difficult”
patient and patient was no longer in the target group
due to changing recruitment strategies.
Discussion
Our comparison of participants to non-participants at 4
of the 11 sites of the OHTN Cohort Study (OCS), a vol-
unteer clinic-based study in Ontario, demonstrated that
participants were similar to non-participants in terms of
the proportions who had a history of injection drug use,
and that participants were only slightly older than non-
participants. Nevertheless, participants differed from
non-participants in a number of important ways. Partici-
pants of the OCS were more likely than non-participants
to be male, more likely to be Canadian-born, had been
infected with HIV longer, had higher CD4 counts, and,
compared to those who were not approached to partici-
pate, were more likely to have virologic suppression. The
latter finding could have been because patients who had
not been approached to participate in the OCS during
the study period (1) had been diagnosed more recently
and had not yet initiated antiretroviral therapy, (2) were
further along in their disease and too sick to participate
or (3) were less adherent to their treatment. After
adjusting for site, the strongest predictors of participa-
tion in the OCS in a multivariable model were an HIV
risk factor of MSM and a longer duration of HIV
infection.
Differences between study participants and non-
participants may limit the generalizability of some re-
search findings. For example, the underrepresentation of
immigrants in cohort studies may result in the under-
estimation of the burden of outcomes more common in
those populations, such as the prevalence of infection
with non-B HIV-1 subtypes, lipohypertrophy (more
common among Black women than White women [15]),
or social factors unique to newcomers to Canada. Never-
theless, the absence of complete representativeness does
not necessarily compromise internal validity for etiologic
analyses of risk factors for health outcomes [16]. For ex-
ample, although individuals with CD4 counts < 200
cells/mm3 were less likely to participate, still 83% of
those approached did consent, and there is no reason to
suspect that their subsequent rate of HIV disease
Table 3 Multivariable generalized logit regression model
of not participating in the study
Characteristics OCS participation OR (9% CI) p value
Site
UHN (ref.) 1
MLMC Declined 0.02 (0.007,0.05) <.0001
Not Approached 0.025 (0.01,0.05) <.0001
OGH Declined 0.37 (0.24,0.58) <.0001
Not Approached 0.80 (0.58,1.09) 0.15
WRH Declined 0.12 (0.01,0.34) <.0001
Not Approached 1.86 (1.31,2.63) 0.0004
Age (per 10 years) Declined 0.98 (0.82,1.18) 0.86
Not Approached 0.98 (0.86,1.12) 0.79
Gender
Female (ref.) 1
Male Declined 1.28 (0.81,2.02) 0.29
Not Approached 1.14 (0.79,1.64) 0.48
Risk factor†
MSM Declined 0.31 (0.20,0.45) <.0001
Not Approached 0.30 (0.21,0.46) <.0001
IDU Declined 0.53 (0.26,1.08) 0.08
Not Approached 0.59 (0.37,0.97) 0.04
Heterosexual Declined 0.70 (0.43,1.14) 0.15
Not Approached 0.59 (0.39,0.89) 0.01
Born in Canada Declined 0.62 (0.43,0.90) 0.012
Not Approached 0.87 (0.65,1.16) 0.35
Years since HIV+
test (per year)
Declined 0.95 (0.93,0.98) 0.0007
Not Approached 0.94 (0.92,0.96) <.0001
On cART Declined 0.61 (0.39,0.97) 0.04
Not Approached 0.91 (0.64,1.31) 0.62
VL <50 copies/mL Declined 1.28 (0.81,2.02) 0.29
Not Approached 0.59 (0.42,0.82) 0.002
CD4 count (cells/mm3)
>500 (ref.) 1
200-500 Declined 1.11 (0.78,1.58) 0.56
Not Approached 1.02 (0.77,1.33) 0.92
<200 Declined 2.20 (1.29,3.75) 0.004
Not Approached 1.51 (0.93,2.15) 0.11
UHN University Health Network, MLMC Maple Leaf Medical Clinic, MSM men
who have sex with men, IDU injection drug use, cART combination
antiretroviral therapy, VL viral load.
† HIV risk factors are not mutually exclusive.
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participants and non-participants.
It should be noted that some clinic patients who had
not been approached to participate in the OCS at the
time of our analysis may have been approached at a laterdate, particularly if the reason for not approaching the
patient was because a patient was new to the clinic,
newly diagnosed, too sick or overwhelmed with other is-
sues at the time, or if the reason the patient was not
approached was due to logistical issues within the site
regarding time and space for approaching patients.
A variety of considerations factor into the decision of
whether or not to participate in a study, including visit
frequency, invasiveness of study procedures, travel time
required, financial reimbursement, education and the
understanding of the importance of research. Language
barriers are also a significant issue in this patient popu-
lation, with a high proportion of recent immigrants.
Rates of participation in the OCS may have differed
according to whether the site was administering the core
questionnaire or the extended questionnaire, since both
the time commitment and the financial reimbursement
varied by type of questionnaire. It is difficult, however,
to obtain accurate and complete information on reasons
for which individual patients declined participation or
were not approached to participate.
Limited research is available on selection biases in vol-
untary HIV cohort studies. A study comparing partici-
pants, non-participants and dropouts of a cohort of men
who have sex with men found significant differences in
race, HIV clinical status, income and education, among
the three groups but that sexual behaviours were similar
[3]. A larger body of work discusses selection biases into
intervention studies for HIV positive individuals. Partici-
pants in a randomized trial of sexual health research
were more likely than non-participants to be women,
non-Caucasian, more educated, with more sexual part-
ners and more likely to be returning patients [2]. Not
having enough time to participate was the most frequent
reason given for not participating. Among patients at a
sexually transmitted disease (STD) clinic, attendance at
a sexual risk reduction workshop was less likely among
younger patients, males, Caucasians and employed indi-
viduals but was not related to sexual behaviour or infec-
tion status [17]. In an HIV prevention trial among HIV
infected individuals, dropouts were more likely to be
younger, depressed and not on antiretroviral medica-
tions [18]. Also, follow-up was related to how much
contact information was collected [19]. Among psy-
chiatric patients in a health promotion study, con-
senters were at higher risk for drug problems than
non-participants and completion of the study was as-
sociated with older age, recent STD diagnosis, and a
psychiatric diagnosis [20].
Limitations of our study include the fact that a minor-
ity of OCS sites agreed to take part in the study and that
there was incomplete data regarding reasons for declin-
ing to participate or not inviting a patient to participate.
Strengths include collection of data from medical charts
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classification of these individuals by whether they were
invited to participate but declined or were not invited to
participate at all.
The OCS has targeted recruitment in recent years in
an effort to make the study population more representa-
tive of the source population of HIV positive individuals
in Ontario seeking medical attention for their HIV dis-
ease. The five priority groups for which recruitment is
focused are patients who were diagnosed within the past
two years, patients younger than 35 years, patients of
Aboriginal descent, injection drug users and individuals
who were born outside of Canada. While targeted re-
cruitment will increase the numbers of participants in
particular subgroups and allow for more detailed study
of these individuals, true representativeness is unlikely
to be achieved in any voluntary study. There will always
be some patients who will be less likely to participate or
whom clinic staff is less likely to approach because of is-
sues such as language barriers, advanced disease and
mental health problems. It is also important to recognize
that attempts to achieve a representative sample must be
balanced with a the desire to maximize internal validity
in cohort studies by ensuring that participants who do
consent are committed volunteers who will be likely to
return for follow-up, thereby minimizing selection bias
introduced by differential attrition.
Conclusion
Lack of representativeness does not diminish the signifi-
cant contribution that a voluntary study with a detailed
questionnaire can make to further the understanding of
HIV disease on social and clinical outcomes but does re-
quire knowledge of the limitations of research with a
voluntary cohort. Comparisons with population-based
data from administrative databases could also provide
important information about the generalizability of re-
sults from voluntary cohort studies.
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